chevron_leftBack
As of 9 June 2026, Aptahem AB (publ) has a market cap of $1.5M USD, ranking #47766 globally and #844 in Sweden.
It ranks #4240 in the Healthcare sector, and #1345 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.5MUSD
14.22M SEK
Enterprise Value
$1.19MUSD
11.26M SEK
Revenue (TTM)
$273.12KUSD
2.59M SEK
EBITDA (TTM)
-$662.78KUSD
-6.26M SEK
Net Income (TTM)
-$685.72KUSD
-6.49M SEK
EBITDA Margin
-242%
Profit Margin
-251%
PS Ratio
5.5
PB Ratio
0.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mikael Lindstam
open_in_new
Employees
3
Founded
2014
Website
aptahem.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 5.9% | -6.1% | -4.5% | -30% | -41% | -54% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
APTA
ISIN: SE0022447173
Shares Out.:
Shares Outstanding:
41.944M1
|
0.6780 SEK |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Aptahem AB (publ)
Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene Biotech for the manufacturing of RNA and oligonucleotides. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
STO: SOBI
|
$14.73B
981K%
139.44B SEK
|
152.8
|
|
STO: CAMX
|
$3.31B
221K%
31.37B SEK
|
42.8
|
|
STO: BIOA-B
|
$2.91B
193K%
27.5B SEK
|
26.9
|
|
STO: SECARE
|
$447.52M
30K%
4.24B SEK
|
85.9
|
|
STO: VICO
|
$298.03M
20K%
2.82B SEK
|
-
|
|
STO: HNSA
|
$291.15M
19K%
2.76B SEK
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
51M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
36M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
24M%
|
97.4
|
|
SIX: RO
|
$322.98B
21M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.68B
19M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$275.9B
18M%
218.9B CHF
|
20.5
|
chevron_leftBack